Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE TEN versus DRYTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE TEN versus DRYTEC.
DIMETANE-TEN vs DRYTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-Ten is a combination of brompheniramine (antihistamine) and phenylephrine (decongestant). Brompheniramine competitively blocks histamine H1 receptors, reducing allergic symptoms; phenylephrine acts as an α1-adrenergic receptor agonist, causing vasoconstriction in nasal mucosa.
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
One tablet (chlorpheniramine maleate 4 mg, phenylephrine HCl 10 mg, methscopolamine nitrate 2.5 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinical context: allows twice-daily dosing; prolonged in renal impairment.
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites; remainder as minor pathways.
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Category C
Category C
Decongestant/Antihistamine Combination
Decongestant